Antagonizing ClpP: A New Power Play in Targeted Therapy for AML
- PMID: 26058072
- DOI: 10.1016/j.ccell.2015.05.013
Antagonizing ClpP: A New Power Play in Targeted Therapy for AML
Abstract
In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) that is overexpressed in a wide range of acute myeloid leukemia (AML) cases, but not in normal hematopoietic precursors. This finding suggests a potentially unique therapeutic targeting opportunity for this difficult-to-treat disease.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment on
-
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.Cancer Cell. 2015 Jun 8;27(6):864-76. doi: 10.1016/j.ccell.2015.05.004. Cancer Cell. 2015. PMID: 26058080 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
